23FBG/620249:
Fibroblast Growth Factor-23 (FGF23), In Situ Hybridization

Test Classification Current Value

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

Test Classification Value Prior to 8/21/2023 3:06pm

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.